Seegene received CE IVDR marking for its Allplex MDRO Assay, a multiplex real-time PCR kit designed to detect multidrug-resistant organisms and associated resistance genes linked to healthcare-associated infections. With IVDR clearance, Seegene can launch the assay in Europe and expand its antimicrobial resistance diagnostics portfolio. The company positions the test for rapid first-line screening before culture-based confirmation, supporting faster infection prevention and control actions in hospitals. Seegene also said it is developing an Allplex MRSA Assay, targeting a 2027 launch. The CE IVDR move highlights continued regulatory momentum for molecular diagnostics and increased demand for actionable hospital-facing tools that reduce time to pathogen and resistance identification.